September 12, 2022 Via Hand Delivery - Personal and Confidential Jason Cole [on file with the Company] Dear Jason,Bluebird Bio, Inc. • November 7th, 2022 • Biological products, (no disgnostic substances) • Massachusetts
As discussed, your employment with bluebird bio, Inc. (“bluebird” or the “Company”) shall terminate effective October 14, 2022. This letter (the “Agreement”) summarizes the terms of your separation from employment and establishes an amicable arrangement under which you release the Company from any claims, and, in return, you receive severance pay and other benefits.
SUBLEASESublease • November 7th, 2022 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances) • Delaware
This instrument is a Sublease (the “Sublease”) dated as of October 31, 2022 (the “Execution Date”) between FINCH THERAPEUTICS, INC., a Delaware corporation (“Sublessor”), and BLUEBIRD BIO, INC., a Delaware corporation (“Sublessee”).
CONSULTING AGREEMENTConsulting Agreement • November 7th, 2022 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS CONSULTING AGREEMENT (together with the attached Business Terms Exhibit, the “Agreement”), is made as of September 12, 2022, and shall be effective as of October 14, 2022 (the “Effective Date”) by and between bluebird bio, Inc., a Delaware corporation with a principal business address at 455 Grand Union Blvd., Somerville, MA 02145 (“bluebird bio”), and Jason F. Cole with an address at [on file with the Company] (“Consultant”). bluebird bio desires to have the benefit of Consultant's knowledge and experience, and Consultant desires to provide services to bluebird bio, all as provided in this Agreement.
CONSULTING AGREEMENTConsulting Agreement • November 7th, 2022 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Consulting Agreement (the “Agreement”) is made effective as of May 26, 2022 (the “Effective Date”), by and between by and between bluebird bio, Inc., a Delaware corporation with a principal business address at 455 Grand Union Blvd, Somerville, MA 02145 (the “Company”) and Danforth Advisors, LLC, a Massachusetts limited liability company, with its principal place of business being 91 Middle Road, Southborough, MA 01772 (“Danforth”). The Company and Danforth are herein sometimes referred to individually as a “Party” and collectively as the “Parties.”
Amendment No. 5 to Clinical and Commercial Supply Agreement Viral Vector ProductBluebird Bio, Inc. • November 7th, 2022 • Biological products, (no disgnostic substances)
This Amendment No. 5 to the Clinical and Commercial Supply Agreement-Viral Vector Product (the “Amendment”) is made effective as of the date of last signature below, (“Amendment Effective Date”) by and between bluebird bio (Switzerland) GmbH (“Company”), and SAFC Carlsbad, Inc., (“SAFC”). Company and SAFC may hereinafter be referred to as a Party or as the Parties. Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Agreement.
